Dr. Reddy's Laboratories Ltd ((BSE: 500124, NSE: DRREDDY, NYSE: ROY, along with its subsidiaries together referred to as "Dr. Reddy's") today announced receipt of approval for Aspirin and Extended-Release Dipyridamole Capsules, a therapeutic equivalent generic version of Aggrenox (aspirin and extended-release dipyridamole) Capsules in the United States market from the U.S. Food and Drug Administration (USFDA). The Company is working towards launching the product.
The Aggrenox brand and generic had U.S. sales of approximately $183 million MAT for the most recent twelve months ending in August 2018 according to IMS Health*.
Dr. Reddy's Aspirin and Extended-Release Dipyridamole Capsules is available in 25 mg/200 mg strength with 60 count bottle size.
Aggrenox is a registered trademark of Boehringer lngelheim.
Shares of DR.REDDY'S LABORATORIES LTD. was last trading in BSE at Rs.2561.15 as compared to the previous close of Rs. 2450.35. The total number of shares traded during the day was 51291 in over 2875 trades.
The stock hit an intraday high of Rs. 2570.55 and intraday low of 2447.15. The net turnover during the day was Rs. 130402829.